Results 51 to 60 of about 12,771 (176)

Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang, Jingmin Li, Meihuan Chen, Hailong Huang   +3 more
wiley   +1 more source

Chronic myeloid leukemia: past, present, future [PDF]

Einstein (São Paulo), 2011
The discovery of the Philadelphia chromosome in 1960, and of the BCR-ABL oncogene in 1984, enabled the development in subsequent years of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history.
Patricia Weinschenker Bollmann, Auro del Giglio   +1 more
doaj   +3 more sources

Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. [PDF]

PLoS ONE, 2012
BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia.
Ludovic Belle, France Bruck, Jacques Foguenne, André Gothot, Yves Beguin, Frédéric Baron, Alexandra Briquet   +6 more
doaj   +1 more source

Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients [PDF]

Blood, 1993
Abstract We report here the results of polymerase chain reaction (PCR) for bcr- abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 ...
K, Miyamura, T, Tahara, M, Tanimoto, Y, Morishita, K, Kawashima, Y, Morishima, H, Saito, S, Tsuzuki, K, Takeyama, Y, Kodera   +9 more
openaire   +3 more sources

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, Volume 117, Issue 4, Page 885-895, April 2026.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source

Bosutinib in the management of chronic myelogenous leukemia

Biologics: Targets & Therapy, 2013
Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an ...
Keller-von Amsberg G, Schafhausen P
doaj  

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia [PDF]

Farmacia Hospitalaria, 2015
Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia.
Begoña San José Ruiz, María Angeles Gil Lemus, María Puy Figuero Echeverria   +2 more
doaj   +1 more source

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) [PDF]

Leukemia, 2002
We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity.
Fischer, T., Reifenrath, C., Hess, G. R., Corsetti, M. T., Kreil, S., Beck, J., Meinhardt, P., Beltrami, G., Schuch, B., Gschaidmeier, H., Hehlmann, R., Hochhaus, A., Carella, A., Huber, C.   +13 more
openaire   +3 more sources

Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells

Biomolecular Concepts, 2021
The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome, Gohari Ladan Hosseini, Barati Mahmood, Safa Majid   +3 more
doaj   +1 more source

Atypical Wounds in Chronic Graft‐Versus‐Host Disease and Peripheral Arterial Disease Caused by Tyrosine Kinase Inhibitors

JEADV Clinical Practice, Volume 5, Issue 1, Page 222-225, March 2026.
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer, K. Malik, C. Willers, M. Augustin   +3 more
wiley   +1 more source